New strategies in radioimmunotherapy for lymphoma Journal Article

  


Authors: Pandit-Taskar, N.; Hamlin, P. A.; Reyes, S.; Larson, S. M.; Divgi, C. R.
Article Title: New strategies in radioimmunotherapy for lymphoma
Abstract: Treatment options for patients with indolent non-Hodgkin's lymphoma historically involved radiation or chemotherapy. Although initial response rates are excellent, treatment is increasingly less effective with each successive relapse. The advent of immunotherapy heralds a new era for the treatment of these patients. Radioimmunotherapy adds the benefits of cytotoxic radiation to immunotherapy and represents a significant addition to the treatment armamentarium. Various antigens for lymphoma have been targeted, of which anti-CD20 antibodies are the furthest in development. Ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA), a 90yttrium-labeled agent, and 131iodine-labeled tositumomab (Bexxar; Corixa, Seatle, WA are approved by the US Food and Drug Administration. Both agents have shown utility in therapy for relapsed and refractory low-grade and transformed lymphomas. This review highlights features of radioimmunotherapy that are relevant to non-Hodgkin's lymphoma, focusing on the two anti-CD20 antibodies. Copyright© 2003 by Current Science Inc.
Keywords: cancer chemotherapy; cancer survival; prednisone; clinical trial; neutropenia; review; cancer recurrence; doxorubicin; advanced cancer; dose response; drug efficacy; drug safety; treatment planning; drug approval; drug targeting; cancer radiotherapy; ibritumomab tiuxetan; rituximab; drug megadose; technetium 99m; cancer grading; medical decision making; cancer immunotherapy; mantle cell lymphoma; anemia; bone marrow suppression; blood toxicity; heart disease; lung disease; thrombocytopenia; cyclophosphamide; vincristine; antineoplastic activity; food and drug administration; tumor antigen; monoclonal antibody; pneumonia; b cell lymphoma; antibodies, monoclonal; acute leukemia; nonhodgkin lymphoma; hybrid protein; iodine 131; radioactive iodine; drug distribution; isotope labeling; iodine radioisotopes; dosimetry; lymphoma, non-hodgkin; radioactivity; lymphoma; phase 3 clinical trial; radiometry; maximum tolerated dose; drug half life; hypothyroidism; radioimmunotherapy; single photon emission computer tomography; indium 111; tositumomab i 131; drug contraindication; follicular lymphoma; yttrium; yttrium radioisotopes; drug binding; 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid; drug conjugation; cd19 antigen; streptavidin; thyrotropin; cd22 antigen; epratuzumab; yttrium 90; astatine 211; myelodysplasia; cd20 antibody; clinical trials, phase iii; iodine 131 anti b1 antibody; iodine-131 anti-b1 antibody; rhenium 186; cd37 antigen; copper 67; monoclonal antibody lym 1; humans; human; article; oncolym
Journal Title: Current Oncology Reports
Volume: 5
Issue: 5
ISSN: 1523-3790
Publisher: Springer  
Date Published: 2003-09-01
Start Page: 364
End Page: 371
Language: English
PUBMED: 12895386
PROVIDER: scopus
DOI: 10.1007/s11912-003-0020-z
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-2142859292&partnerID=40&md5=21269ddab8c9a447502fb32da5641955
Notes: Export Date: 25 September 2014 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Chaitanya Divgi
    163 Divgi
  2. Neeta Pandit-Taskar
    343 Pandit-Taskar
  3. Paul Hamlin
    278 Hamlin
  4. Steven M Larson
    959 Larson
  5. Susan Clarisa E Reyes
    3 Reyes
Related MSK Work